Plus Therapeutics, a pharmaceutical company engaged in developing targeted radiotherapeutics for rare and difficult-to-treat cancers, announced that it has expanded its partnership with Medidata, a Dassault Systèmes company.The expanded partnership is aimed at faster enrollment, improved patient access to therapy and reduce clinical trial costs in Plus Therapeutics’ planned forthcoming Phase 2 registrational trial of Rhenium-186 NanoLiposome (186RNL) in recurrent glioblastoma (GBM). The partnership will utilize Medidata’s Synthetic Control Arm® (SCA) platform that facilitates the use of historical clinical trial (HCT) data in a manner that historically has been favorably received by the U.S. Food and Drug Administration. The expanded partnership follows a successful preliminary assessment stage intended to determine project feasibility and probability of success.

To read more please visit:

Plus Therapeutics and Medidata Announce Expanded Clinical Trial Partnership

Source: PLUS